Literature DB >> 23896736

[Disputed therapy recommendations for infectious endocarditis].

W V Kern.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23896736     DOI： 10.1007/s00108-013-3338-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  9 in total

Review 1.  [Infective endocarditis].

Authors:  B Plicht; A Kaasch; W V Kern
Journal:  Dtsch Med Wochenschr       Date:  2011-11-22       Impact factor: 0.628

2.  Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America.

Authors:  Douglas R Osmon; Elie F Berbari; Anthony R Berendt; Daniel Lew; Werner Zimmerli; James M Steckelberg; Nalini Rao; Arlen Hanssen; Walter R Wilson
Journal:  Clin Infect Dis       Date:  2012-12-06       Impact factor: 9.079

3.  Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Ann F Bolger; Matthew E Levison; Patricia Ferrieri; Michael A Gerber; Lloyd Y Tani; Michael H Gewitz; David C Tong; James M Steckelberg; Robert S Baltimore; Stanford T Shulman; Jane C Burns; Donald A Falace; Jane W Newburger; Thomas J Pallasch; Masato Takahashi; Kathryn A Taubert
Journal:  Circulation       Date:  2005-06-14       Impact factor: 29.690

4.  Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia.

Authors:  Young Ju Jung; Younsuck Koh; Sang-Bum Hong; Joo Won Chung; Sang Ho Choi; Nam Joong Kim; Mi-Na Kim; Ik Su Choi; Song Yi Han; Won-Dong Kim; Sung-Cheol Yun; Chae-Man Lim
Journal:  Crit Care Med       Date:  2010-01       Impact factor: 7.598

5.  Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections.

Authors:  P Van der Auwera; J Klastersky; J P Thys; F Meunier-Carpentier; J C Legrand
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

Review 6.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

7.  Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

Authors:  D P Nicolau; C D Freeman; P P Belliveau; C H Nightingale; J W Ross; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

8.  Clinical study of combination therapy with oxacillin and rifampin for staphylococcal infections.

Authors:  P Van der Auwera; F Meunier-Carpentier; J Klastersky
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

9.  Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial.

Authors:  Guy Thwaites; Cressida Auckland; Gavin Barlow; Richard Cunningham; Gerry Davies; Jonathan Edgeworth; Julia Greig; Susan Hopkins; Dakshika Jeyaratnam; Neil Jenkins; Martin Llewelyn; Sarah Meisner; Emmanuel Nsutebu; Tim Planche; Robert C Read; Matthew Scarborough; Marta Soares; Robert Tilley; M Estée Török; John Williams; Peter Wilson; Sarah Wyllie; A Sarah Walker
Journal:  Trials       Date:  2012-12-18       Impact factor: 2.279
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.